125 related articles for article (PubMed ID: 20815108)
41. Recent HIV-1 infection: to treat or not to treat, that is the question.
Tossonian H; Conway B
J Infect Dis; 2012 Jan; 205(1):10-2. PubMed ID: 22180623
[No Abstract] [Full Text] [Related]
42. Tenofovir gel--the new HIV prevention 'banker'?
Bateman C
S Afr Med J; 2007 Jul; 97(7):496, 498. PubMed ID: 17805450
[No Abstract] [Full Text] [Related]
43. Pre-exposure prophylaxis for HIV infection: what if it works?
Paxton LA; Hope T; Jaffe HW
Lancet; 2007 Jul; 370(9581):89-93. PubMed ID: 17617276
[No Abstract] [Full Text] [Related]
44. HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.
Garrett NJ; Werner L; Naicker N; Naranbhai V; Sibeko S; Samsunder N; Gray C; Williamson C; Morris L; Abdool-Karim Q; Abdool-Karim SS
J Acquir Immune Defic Syndr; 2015 Jan; 68(1):55-61. PubMed ID: 25247433
[TBL] [Abstract][Full Text] [Related]
45. Novel HIV-1 treatment Stribild™ gains regulatory approval.
Breeze S
Expert Rev Clin Pharmacol; 2012 Nov; 5(6):613. PubMed ID: 23234321
[No Abstract] [Full Text] [Related]
46. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
Albrecht H
AIDS Clin Care; 2008 Apr; 20(4):28. PubMed ID: 19271262
[No Abstract] [Full Text] [Related]
47. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
[TBL] [Abstract][Full Text] [Related]
48. Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Checking up on ddI and tenofovir in people with HIV/AIDS.
TreatmentUpdate; 2003; 15(3):4-5. PubMed ID: 17216846
[No Abstract] [Full Text] [Related]
49. Oral tenofovir arm of VOICE trial discontinued early.
McEnery R
IAVI Rep; 2011; 15(5):21. PubMed ID: 22121550
[No Abstract] [Full Text] [Related]
50. Tenofovir and abacavir combination therapy: lessons learned from an urban clinic population.
Gilliam BL; Sajadi MM; Amoroso A; Davis CE; Cleghorn FR; Redfield RR
AIDS Patient Care STDS; 2007 Apr; 21(4):240-6. PubMed ID: 17461718
[TBL] [Abstract][Full Text] [Related]
51. Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens.
van Leth F; Prins JM; Lange JM; Geerlings SE
AIDS; 2005 Oct; 19(15):1722-3. PubMed ID: 16184059
[No Abstract] [Full Text] [Related]
52. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
[No Abstract] [Full Text] [Related]
53. Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.
Mansoor LE; Karim QA; Werner L; Madlala B; Ngcobo N; Cornman DH; Amico KR; Fisher J; Fisher WA; Macqueen KM; Karim SS
AIDS Behav; 2014 May; 18(5):841-8. PubMed ID: 24633717
[TBL] [Abstract][Full Text] [Related]
54. New once-daily HIV combination better tolerated.
Expert Rev Anti Infect Ther; 2004 Dec; 2(6):826. PubMed ID: 15566325
[No Abstract] [Full Text] [Related]
55. CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.
Valley-Omar Z; Sibeko S; Anderson J; Goodier S; Werner L; Arney L; Naranbhai V; Treurnicht F; Abrahams MR; Bandawe G; Swanstrom R; Karim QA; Karim SS; Williamson C
J Infect Dis; 2012 Jul; 206(1):35-40. PubMed ID: 22551813
[TBL] [Abstract][Full Text] [Related]
56. CD4 count improvement following tenofovir to abacavir switch in a patient with persistent lymphopenia despite an undetectable viral load.
Condoluci DV; Andrews M; Luber AD
AIDS Read; 2008 Aug; 18(8):410-2. PubMed ID: 18770899
[TBL] [Abstract][Full Text] [Related]
57. [HIV infected women with intense bone and muscular pain and general weakness].
Pérez-Rivera AÁ; Sáez P; León E; Lozano de León-Naranjo F
Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):308-10. PubMed ID: 21334782
[No Abstract] [Full Text] [Related]
58. Tenofovir, equivalence, and noninferiority.
Parienti JJ
JAMA; 2004 Oct; 292(16):1951; author reply 1951-2. PubMed ID: 15507576
[No Abstract] [Full Text] [Related]
59. Compassionate use for tenofovir.
AIDS Patient Care STDS; 2000 Feb; 14(2):101-2. PubMed ID: 10743524
[No Abstract] [Full Text] [Related]
60. HIV pre-exposure prophylaxis in injecting drug users.
Karim SS
Lancet; 2013 Jun; 381(9883):2060-2. PubMed ID: 23769217
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
